Advaxis – $30 Million Registered Direct Offering

New York – August 30, 2016 – Cooley advised the placement agents on Advaxis, Inc.’s registered direct offering of 2,244,443 shares of common stock resulting in gross proceeds of approximately $30.3 million.

Advaxis is a clinical-stage biotech company developing multiple cancer immunotherapies based on its proprietary Lm Technology.

Jefferies and Barclays acted as lead placement agents for the offering. Cantor Fitzgerald & Co., Guggenheim Securities, Janney Montgomery Scott and H.C. Wainwright & Co. acted as co-placement agents.

The Cooley corporate and securities team advising the placement agents was comprised of Div Gupta, Charlie Kim, Brent Siler, Jonie Kondracki and Denny Won.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law. 

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.